The UK and US have established a important trade agreement that will keep no duties on UK pharmaceutical exports entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to boost funding on drugs through the NHS. This pledge ensures that tariffs on these vital exports will remain at nothing for a period of 36 months.
This development comes after earlier threats to hike duties on patented drug imports, with potential rates discussed up to 100%.
"This arrangement with the United Kingdom bolsters the worldwide climate for innovative medicines and introduces long-overdue balance to transatlantic pharmaceutical trade," a release noted.
Economic Importance
Medicines constitute one of the the United Kingdom's biggest exports to the US, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products totaling £11.1bn to the US. This amount represented 17.4% of British export trade in that timeframe.
"This deal secures jobs, increases funding and sets the stage for the UK to become a global hub for medical research," a government official remarked.
Specific British Pledges
The deal involves several specific commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to increase total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The percentage manufacturers must return to the NHS to prevent overspending will be capped at fifteen percent. In the past, repayments exceeded 20%.
Recent Tensions
The deal takes place against a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
The disagreement were exacerbated by assertions that American customers were paying a premium for the same drugs than consumers in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or cancelled, while substantial funding commitments have been directed toward US facilities.
A senior figure stated that the NHS must invest a greater share on treatments, noting that its spending on drugs had declined as a percentage of its resources over the previous ten-year period.
